Specialised AI solutions help screen eye and cardiovascular diseases earlier

The Eyetelligence Assure platform works in conjunction with any fundus camera and PC, and does not require image upload via the internet.

By Optain (Australia)

Eyetelligence, an Australian-based, international medtech company, has developed Eyetelligence Assure, an advanced AI software solution that analyses retinal images for features of the three major blinding eye diseases: glaucoma, referable diabetic retinopathy and referable neovascular age-related macular degeneration.

Backed by peer-reviewed publications and journals, Eyetelligence’s deep learning technology is designed to empower clinicians to make more informed clinical decisions with speed, accuracy, and confidence to ensure the best health outcomes for their patients. Professor Mingguang He, Professor of Ophthalmic Epidemiology at the University of Melbourne and Eyetelligence Chief Medical Officer, says: “AI has evolved from computer software in the laboratory to clinical adaptation in many imagedriven practices, including ophthalmology.

“Enabled by a combination of the availability of large datasets and substantially improved computing power, deep learning algorithms (DLAs) have created unprecedented opportunities for substantially improved accuracy in automated diagnosis and classification of medical images. This automated diagnosis, which makes eye care less dependent on human input, is improving accessibility, efficiency, and cost-effectiveness, making ocular disease diagnosis and management quicker, cheaper, and more consistent.”

The Eyetelligence Assure platform works in conjunction with any fundus camera and PC, and does not require image upload via the internet, which means every patient’s identity, information and clinical data are protected.

“In the optometry setting, our aim is to provide practitioners and patients alike with peace of mind – because they know that Eyetelligence detects cataract, age related macular degeneration, glaucoma and diabetic retinopathy with 95% accuracy regardless of the practitioner’s level of experience,” Prof. Ming explained.

As the eye is the body’s only organ that provides a microvascular profile Eyetelligence has also developed Eyetelligence Microvascular, a non-invasive platform to detect early signs of cardiovascular disease. Eyetelligence Microvascular makes it easy to understand the patient’s level of risk so that management with counselling and medicines can begin to minimise the risk.

Eyetelligence Microvascular report shows:

• 5-year risk score as a percentage of the potential for a cardiovascular event
• Comparison of health status against other people with a similar age and gender

Eyetelligence harnesses the power of AI To provide affordable clinical support tools that make disease screening easy, anytime, anywhere.

Visit eyetelligence.ai

Interested to know more?

To learn about how stakeholders are redefining healthcare in the GCC and MENA region, read the full PrecisionMed International May 2023 magazine online here.

Published in PrecisionMed International Magazine (MENA Edition)